Analysis of estrogen and progesterone receptor gene polymorphisms in leiomyoma

Background Leiomyoma, one of the most common benign tumors, causes morbidity during the reproductive years in women. The molecular pathogenesis of the disease is not clear. Leiomyomas are hormone‐sensitive tumors affecting around 20%‐25% of women. Gene polymorphism studies could be important and exp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical laboratory analysis 2019-03, Vol.33 (3), p.e22704-n/a
Main Authors: Toprak, Muhammed, Ates, Omer, Ozsoy, Asker Zeki, Bozkurt, Nihan, Sezer Sondas, Saime, Cakmak, Bülent, Yılmaz Dogru, Hatice, Delibas, İlhan Bahri, Demirturk, Fazlı
Format: Article
Language:English
Subjects:
Adult
C gene
Case-Control Studies
estrogen
Female
Fibroids
Gene frequency
Gene polymorphism
Genetic factors
Genetic markers
Humans
leiomyoma
Leiomyoma - epidemiology
Leiomyoma - genetics
Middle Aged
Morbidity
PCR
Polymerase Chain Reaction
Polymorphism
Polymorphism, Genetic - genetics
Primers
Progesterone
progesterone receptor
Receptors, Estrogen - genetics
Receptors, Progesterone - genetics
Steroid hormones
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Leiomyoma, one of the most common benign tumors, causes morbidity during the reproductive years in women. The molecular pathogenesis of the disease is not clear. Leiomyomas are hormone‐sensitive tumors affecting around 20%‐25% of women. Gene polymorphism studies could be important and explaining in the evaluation of multifactorial diseases such as leiomyoma. Polymorphisms involving genes responsible for the synthesis and signalization of steroid hormones could be used as genetic markers for hormone‐related conditions. The purpose of this study was to analyze the effect of ERα‐351 XbaI A/G, ERα‐397 PvuII T/C, and progesterone receptor (PGR) PROGINS polymorphisms on the development of leiomyomas. Material and Methods In this study, 213 samples (103 leiomyoma patients and 110 healthy controls) participated. The ERα‐351 XbaI A/G and ERα‐397 PvuII T/C gene polymorphisms were analyzed using PCR‐RFLP method. PGR PROGINS polymorphism was analyzed by PCR method with specific primers. Results The genotype distribution and allele frequency of the ERα‐351 XbaI A/G, ERα‐397 PvuII T/C, and PGR PROGINS polymorphisms were not statistically different between leiomyoma patient and control groups (p > 0.05). Conclusion This study reflects that ERα and PGR PROGINS polymorphisms may not be one of the many genetic factors for leiomyoma susceptibility.
ISSN:0887-8013
1098-2825
DOI:10.1002/jcla.22704